✦ LIBER ✦

Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes

✍ Scribed by Dr. Christopher R. Chitambar; Joseph A. Libnoch; William G. Matthaeus; Robert C. Ash; Paul S. Ritch; Tom Anderson

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 443 KB
Volume: 37
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830370207

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuous infusion of 5-fluorouracil an

Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma

✍ Yong-Suk Chung; Yoshito Yamashita; Tohru Inoue; Tasuku Matsuoka; Bunzo Nakata; N 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

City Uni-11 cases, for an overall response rate of 50%. Patients with good performance versity Medical School, Osaka, Japan. status (PS) (0-1) and differentiated histologic type showed higher response rates (50.0% and 63.6%, respectively) than patients with poor PS (2 or 3) and undifferenti-2 Insti

Continuous intravenous infusions of 5-fl

Continuous intravenous infusions of 5-fluoro-2′-deoxyuridine in the treatment of solid tumors

✍ Ronald C. Deconti; Stephen R. Kaplan; Rose J. Papac; Paul Calabresi 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

Evaluation of low dose continuous infusi

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study

✍ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 2 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology

Cisplatin, continuous-infusion 5-fluorou

Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung

✍ Catherine A. Wheeler; Lawrence N. Shulman; Steven E. Come; Lowell E. Schnipper; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 2 views

Forty-one patients with unresectable non-small cell carcinoma of the lung (NSCCL) were treated with cisplatin 20 mg/m2/d for 5 days as a daily bolus injection, 5-fluorouracil 800 mg/m2/d by continuous infusion for 5 days, and intermediate-dose methotrexate 200 mg/m2 on days 15 and 22 of a 28-day cyc

Bowel rest, intravenous hydration, and c

Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma

✍ Nicholas J. Petrelli; Miguel Rodriguez-Bigas; Youcef Rustum; Lemuel Herrera; Pat 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB 👁 2 views

A phase II multi-institutional trial of

A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A southwest oncology group study

✍ Louise M. Morrell; Ardalan Bach; Stephen P. Richman; Phyllis Goodman; Thomas R. 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB 👁 2 views